PRIMARY STUDY
Chronic Pain Treatment With Cannabidiol in Kidney Transplant Patients in Uruguay
Key Findings: This study found that patients with a kidney transplant who were taking cannabidiol (CBD) for pain had no negative effects on kidney function, was overall safe, well tolerated, and with only mild adverse effects.
Type of Study: Clinical Trial
Study Sample Size: 7
Study Result: Positive
Study Location(s): Uruguay
Year of Pub: 2018
Cannabinoids Studied: Cannabidiol (CBD)
Phytocannabinoid Source: Not Applicable
Chemotype: Chemotype III
DOSING DETAILS 
Study Dosing Objective: Safety Profile
Established Protocol: Adverse effects
Cannabinoid Ratio: (CBD) 0 
Dosing Regimen: CBD (100-300 mg/day)
Starting Dose: 100 mg/day
Maximum Dose: 300 mg/day
Treatment Duration: 3 weeks
Clinical Relevance: There were no severe adverse effects from CBD, and did not appear to alter creatinine, blood count, liver function, or liver enzymes, but may have an effect on serum levels of tacrolimus.
Adverse Events: Adverse effects were nausea, dry mouth, dizziness, drowsiness, and intermittent episodes of heat. Persistent nausea for one patient led to dose reduction to 50 mg/d on day 4.
Additional Notes: Pharmacodynamic Study Data
Link to study
